Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.25M | $0.00 | — | $0.00 | $1.09M | $1.11M | -$227K | $1.06M | $486K | $1.27M |
| Revenue growth | — | -100.0% | — | — | — | 1.8% | -120.5% | 568.7% | -54.3% | 161.1% |
| Operating income | -$10.2M | -$14.2M | -$24.6M | -$20.8M | -$17.9M | -$47.8M | -$59.3M | -$33.0M | -$56.0M | -$72.1M |
| Operating margin | -819.9% | — | — | — | -1646.1% | -4308.7% | 26109.3% | -3103.5% | -11517.1% | -5683.7% |
| Net income | -$10.3M | -$14.3M | -$24.6M | -$20.8M | -$17.9M | -$47.8M | -$59.2M | -$29.4M | -$51.4M | -$69.7M |
| Net margin | -820.4% | — | — | — | -1646.1% | -4307.2% | 26100.4% | -2759.6% | -10579.8% | -5491.3% |
| EPS (diluted) | -$1.54 | -$1.12 | -$0.90 | -$0.50 | -$0.49 | — | -$8.51 | -$1.52 | -$1.67 | -$1.83 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.26M | -$9.06M | -$14.5M | -$15.8M | -$12.1M | -$45.3M | -$49.7M | -$25.8M | -$42.1M | -$66.4M |
| Capital expenditures | $239K | $1.60K | $174K | $0.00 | $275K | $0.00 | $528K | $0.00 | — | — |
| Free cash flow | -$7.50M | -$9.06M | -$14.7M | -$15.8M | -$12.3M | -$45.3M | -$50.2M | -$25.8M | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.92M | $10.4M | $13.1M | $1.36M | $103M | $68.1M | $16.6M | $119M | $67.1M | $30.8M |
| Total assets | $3.71M | $11.3M | $14.0M | $5.77M | $108M | $74.6M | $21.1M | $124M | $84.3M | $48.6M |
| Total liabilities | $3.10M | $4.36M | $6.94M | $11.5M | $16.3M | $9.93M | $9.01M | $9.37M | $14.0M | $13.0M |
| Shareholders' equity | $616K | $6.92M | $7.08M | -$5.73M | $92.0M | $64.7M | $12.1M | $114M | $70.4M | $35.5M |
| Retained earnings | -$142M | -$157M | -$181M | -$202M | -$220M | -$268M | -$327M | -$356M | -$408M | -$477M |
| Shares (wtd avg diluted) | — | — | — | — | 86.1M | 6.60M | 6.96M | 19.4M | 30.9M | 38.1M |
Every figure is extracted from Vistagen Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.